LabCorp to acquire Chiltern for $1.2B in cash

Monday, July 31, 2017

LabCorp, a global life sciences company, and Chiltern, a specialty CRO, announced that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern will become part of LabCorp’s Covance segment.

[Read More]

Chiltern launches Medidata Rave Value Accelerators

Monday, June 12, 2017

Chiltern, a global CRO, has announced the release of its new Medidata Rave Value Accelerators, a system of tools designed to capture, manage and report clinical research data. The tools streamline the clinical trial process and help trial sponsors cut the time, cost and effort of bringing a new device to market.

[Read More]

Three Questions: David Izard, Chiltern

Tuesday, May 30, 2017

CWWeekly presents this biweekly feature as a spotlight on issues that executives in clinical research face. This week, writer Sony Salzman spoke with David Izard, senior director, Clinical Data Standards at Chiltern. He co-authored the white paper “The Case For Embracing The FDA’s Endorsed Data Standards.”

[Read More]

PSI, INC, Chiltern take top site ratings

Saturday, April 1, 2017

Investigators report their working relationships with CROs have become more effective during the past two years, according to a new CenterWatch survey, and nearly half said overall CRO performance, for the first time, matches that of sponsor companies.

[Read More]

Chiltern expands in Bangalore, India

Wednesday, February 1, 2017

Chiltern, a global CRO, has announced the opening of its new process and technology center in Bangalore, India. The new office is a direct result of the company’s continued success and fulfills a need to further enhance its global data capabilities.

[Read More]

Big Data in clinical trials: Promise and pitfalls

Monday, August 15, 2016

Privacy versus medical progress. Proprietary ownership versus public information. Cost-effectiveness versus unnecessary burdens. Welcome to the swirl of opinions and emotions around Big Data and its potential—or not—in the clinical trials industry.

[Read More]